MAP2K7 and melanoma: MEK is chronically activated in the majority of melanomas, and MEK activation is a prime cause of resistance to BRAF inhibitors.10 Therefore, we focused on factors that are under potential regulation of MEK signaling as we reasoned these could be potential candidates for therapeutic intervention of melanomas resistant to BRAF/MEK inhibitors.